Dismantling the Immunosuppressive Barrier of the Pancreatic Cancer Microenvironment via lncRNA to Induce Macrophage Reprogramming
Background
Pancreatic ductal adenocarcinoma (PDAC) is a fatal, intractable malignant tumor with a 5-year survival rate of less than 12% after diagnosis. Even immunotherapy, which has become a mainstay of modern anticancer treatment, struggles against pancreatic cancer because the complex and robust tumor microenvironment (TME) surrounding the tumor forms a powerful immunosuppressive barrier.
The immune cell that occupies the most overwhelming proportion within this microenvironment is known as tumor-associated macrophages (TAM). While macrophages in a normal state attack external invaders or mutated cells, in the pancreatic cancer environment, they are tamed by signals emitted from cancer cells and undergo polarization to an M2 phenotype. Macrophages transformed into the M2 phenotype promote cancer cell metastasis and invasion while blocking the access of cytotoxic T cells. They essentially act as key facilitators in enhancing treatment resistance. To inhibit tumor growth, it is necessary to reverse M2-TAM polarization and restore anti-cancer immunity; however, it has been difficult to clearly identify precise regulatory molecules that alter the properties of macrophages.
Key Findings
Recently, researchers comprehensively identified that long non-coding RNA (lncRNA), a type of non-coding RNA, is a key factor coordinating macrophage polarization within the pancreatic cancer microenvironment. Known as transcripts that do not directly produce proteins, lncRNAs induce M2 polarization across three dimensions: transcriptional regulation, epigenetic modification, and post-transcriptional control.
Specifically, lncRNAs recruit chromatin remodeling enzymes to change gene expression patterns or activate competitive endogenous RNA (ceRNA) networks to protect transcription factors necessary for M2 differentiation. They act as sponges that absorb microRNA (miRNA), preventing the degradation of proteins that induce M2 signaling. Mechanisms where they directly activate major intracellular signaling pathways, such as STAT3 or NF-κB, to amplify the secretion of immunosuppressive cytokines have also been confirmed.
Accordingly, a therapeutic strategy to reprogram the tumor microenvironment by controlling abnormally activated lncRNAs has been proposed. Representative methods include targeted knockdown using small interfering RNA (siRNA), genome editing based on CRISPR gene scissors, and antisense oligonucleotide (ASO) treatment. By combining small-molecule compounds that block lncRNA downstream signaling pathways with nanoparticle-based delivery vehicles, it is possible to accurately deliver RNA therapeutics, which are prone to degradation, to tumor-associated macrophages (TAMs) within tumor tissue, thereby repolarizing the M2 phenotype into an anti-tumor M1 phenotype.
Significance and Outlook
This review is noteworthy for presenting the possibility of reconstructing the previously impenetrable immunosuppressive environment of pancreatic cancer at the molecular level. A strategy to convert macrophages into the tumor-attacking M1 type, rather than simply removing them, is evaluated as a powerful alternative that can maximize the synergistic effects with existing immune checkpoint inhibitors. Furthermore, analyzing lncRNA expression patterns associated with M2 polarization can serve as a biomarker for precisely predicting patient prognosis and designing optimal treatment pathways.
Challenges also remain. lncRNAs have complex secondary structures and low target delivery efficiency within tumor tissue, making it difficult to ensure safety upon administration in humans. The validation of highly efficient targeted nano-platforms capable of delivering drugs deep into pancreatic tumors while minimizing potential off-target side effects on normal immune cells is expected to be the watershed for future clinical translation.
Pancreatic ductal adenocarcinoma (PDAC), which is the most common type of pancreatic cancer (PC), carries a poor prognosis with a 5-year survival rate of less than 12%. Suboptimal therapeutic responses are primarily attributed to the immunosuppressive features of the tumor microenvironment (TME). In the PDAC TME, tumor-associated macrophages (TAMs) constitute the dominant immune cell population. Polarization of TAMs toward the M2 phenotype promotes tumor progression, immune escape, therapeutic resistance, and disease advancement. Recent studies have demonstrated that long non-coding RNAs (lncRNAs) regulate M2-TAM polarization and PDAC progression via transcriptional, epigenetic, and post-transcriptional mechanisms. This review summarizes key lncRNAs involved in TAM polarization in PDAC, highlighting their roles in inducing the M2 phenotype and promoting PDAC progression through epigenetic modifications, ceRNA networks, and signal transduction pathways. Based on these regulatory mechanisms, potential therapeutic strategies targeting lncRNAs, such as siRNA-mediated knockdown, CRISPR-based editing, antisense oligonucleotides, downstream-targeting strategies, and nanoparticle delivery systems, may provide more precise control over lncRNA activity to repolarize TAMs and reverse immunosuppression in the TME. Furthermore, advances in developing clinical prognostic models that incorporate lncRNAs linked to M2-TAMs offer potential for refined patient outcome prediction and the identification of tailored PDAC treatment options.
The lncRNA-based macrophage repolarization strategy can be implemented as a combination therapy pipeline combined with standard pancreatic cancer chemotherapy or immune checkpoint inhibitors. A realistic application model is the development of companion diagnostic kits that predict the ratio of aggressive M2-TAMs by measuring specific lncRNA expression levels in patient biopsy tissues using digital PCR or RNA sequencing. By administering targeted antisense oligonucleotides (ASOs) loaded into lipid nanoparticles (LNPs) to penetrate the tumor stromal barrier and reprogram tumor-associated macrophages (TAMs), this approach can directly contribute to the development of next-generation cell-targeted therapeutics that convert pancreatic cancer from a "cold" to an immunologically "hot" tumor state with activated immune responses.